INDEX study: intravenous dexamethasone palmitate for prophylaxis of postoperative nausea and vomiting: a study protocol for a randomised controlled study Authors: Hao Ren, Chunmei Zhao, Linsong Yuan, Lan Meng, Ying Shen, Fang Luo Published: 2025 ABSTRACT AbstractIntroductionDexamethasone is commonly used to prevent postoperative nausea and vomiting (PONV). However, PONV is an unresolved complex problem; even with preoperative dexamethasone administration, 14.0%–26.3% of patients undergoing minimally invasive endoscopic procedures still experience PONV within 24 hours postoperatively. Compared with dexamethasone, dexamethasone palmitate has a long-lasting anti-inflammatory effect, two to five times that of traditional water-soluble dexamethasone, with fewer adverse events. This trial aims to assess the efficacy and safety of preoperative dexamethasone palmitate administration on postoperative PONV.Methods and analysisThe INDEX trial is a multicentre, open-label, randomised, positive-controlled trial. A total of 588 patients will be recruited from three centres in China. Eligible patients are adults (aged 18–65 years) who undergo elective minimally invasive endoscopic surgery (laparoscopic or thoracoscopic surgery) under general anaesthesia. Eligible patients will be randomly assigned (1:1) to the dexamethasone palmitate or dexamethasone group. Patients in the dexamethasone palmitate group will receive intravenous injection of 8 mg of dexamethasone palmitate (containing 5 mg of dexamethasone), and those in the dexamethasone group will receive 5 mg of dexamethasone after anaesthesia induction and before surgical incision. The primary endpoint will be the incidence of PONV within the first 24 hours postoperatively. Secondary outcomes will include the incidence of PONV, postoperative nausea, postoperative vomiting, number of vomiting or retching episodes, severity of PONV, participant satisfaction, use of rescue antiemetic drugs and quality of postoperative recovery. The safety of participants will be monitored. A primary analysis will be conducted to evaluate between-group differences in the incidence of PONV in the intention-to-treat population and within the first 24 hours postoperatively. We will also perform a sensitivity analysis to evaluate the effect of missing values in the outcome parameters on the results. There is no plan to conduct an interim analysis.Ethics and disseminationEthical approval was obtained from the Institutional Review Board of Beijing Tiantan Hospital Affiliated to Capital Medical University (KY 2025-041-02-01). The results will be disseminated in open-access publications and plain-language summaries.Trial registration number NCT06981754 Keywords: Randomized Controlled Trial, Adult anaesthesia, Minimally invasive surgery, Clinical Trial STRENGTHS AND LIMITATIONS OF THIS STUDY The INDEX trial is a multicentre, open-label, randomised, positive-controlled trial. The INDEX trial is a multicentre, open-label, randomised, positive-controlled trial. Multiple imputation will be used to handle missing data. Multiple imputation will be used to handle missing data. Subgroup analyses are prespecified for key demographic and clinical factors to explore heterogeneity of treatment effects. Subgroup analyses are prespecified for key demographic and clinical factors to explore heterogeneity of treatment effects. The open-label design may introduce performance and detection bias. The open-label design may introduce performance and detection bias. Introduction Postoperative nausea and vomiting (PONV) are common adverse reactions to surgery under general anaesthesia. The incidence rate of PONV in the general surgical population is estimated to be 30%, and the incidence rate of high-risk patients is as high as 80% when no prophylactic antiemetics are administered.1 2 Age <25 years, female sex, surgery time exceeding 3 hours and intravenous infusion exceeding 25 mL/kg are all considered high-risk factors for PONV.3 4 Furthermore, common pain control strategies include patient-controlled analgesia with opioid drugs, often leading to PONV.5 The occurrence of PONV may lead to patient dissatisfaction, longer stay in the postoperative recovery room (PACU), an increased risk of unplanned readmission and increased medical costs.6,9 Currently, corticosteroids are one of the most commonly used drugs for PONV prevention, along with serotonin receptor antagonists, prokinetic drugs, antipsychotics and other antiemetic drugs.10 11 Dexamethasone, a common corticosteroid, is the first-line choice for the prevention and treatment of PONV2 and has the advantage of effectively combating opioid-induced PONV in the neural axis.12 Single-dose intravenous injection of dexamethasone (4 mg–10 mg) during surgery can effectively prevent PONV.13,15 Dexamethasone can be used alone or in combination with one or two other types of antiemetic drugs.2 When dexamethasone is injected intravenously, its concentration reaches its peak within 2–12 hours and often lasts for a biological half-life of up to 72 hours.16 Its mechanism of action in PONV is not yet precise, but it may result from combining these non-genomic and genomic interactions. However, PONV remains an unsolved complex problem; for example, even with preoperative dexamethasone administration, 14.0%–26.3% of patients undergoing minimally invasive endoscopic procedures still experience PONV within 24 hours postoperatively.14 17 Furthermore, a prospective study showed that blood glucose may increase by 30–45 mg/dL after 4/8 mg dexamethasone injection.18 The stress response to surgery can also stimulate endogenous corticosteroid responses and increase blood glucose levels while reducing the peripheral utilisation of glucose.19 The hyperglycaemic response resulting from intravenous dexamethasone administration remains a clinical concern, especially in patients with diabetes.16 20 21 Therefore, more effective and safer PONV prevention measures should be considered. Dexamethasone palmitate has unique structural and functional properties, compared with dexamethasone. It exerts anti-inflammatory effects which are two to five times that of traditional water-soluble dexamethasone. Mechanistically, the lipid microsphere formulation slowed down the local release of the active metabolite dexamethasone locally for 1–2 weeks through the gradual hydrolysis of esterases in vivo.22 Dexamethasone palmitate exerts an inflammatory tendency and a small systemic distribution. Therefore, it has a better safety profile than traditional aqueous formulations.23 At equivalent doses of the active dexamethasone component, intravenous administration of dexamethasone palmitate is hypothesised to exhibit superior efficacy in preventing PONV compared with conventional dexamethasone formulations, with fewer adverse events (AEs). This study protocol presents the design and methodology of a randomised controlled trial that will assess the effects and safety of preoperative dexamethasone palmitate on postoperative PONV. Methods Study design The INDEX trial is a multicentre, open-label, randomised, positive-controlled trial. We plan to begin with participants from three centres: Beijing Tiantan Hospital, affiliated with Capital Medical University; Beijing Ditan Hospital, affiliated with Capital Medical University; and Daxing District People’s Hospital, Capital Medical University. This trial is registered at https://clinicaltrials.gov/ (NCT06981754). The trial protocol was approved by the Institutional Review Board (IRB) of Beijing Tiantan Hospital, Affiliated with Capital Medical University (KY 2025-041-02-01). After a detailed explanation by the researcher, the participants decide whether to participate in the trial and provide written informed consent. The participant consent form is provided in the online supplemental file 1. The study will adhere to the Declaration of Helsinki. The study began enrolling participants on 17 June 2025 and is expected to be completed by 31 December 2026. The workflow of the study is presented in online supplemental file 2. Inclusion and exclusion of participants Eligible patients are adults (aged 18–65 years) with the ability to provide written informed consent for elective minimally invasive endoscopic surgery (laparoscopic or thoracoscopic surgery) under general anaesthesia. The exclusion criteria are Known to be allergic to dexamethasone Known to be allergic to dexamethasone Any systemic glucocorticoids within 3 months before trial entry Any systemic glucocorticoids within 3 months before trial entry History of severe heart disease, liver/kidney failure or systemic rheumatic diseases (including rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus) History of severe heart disease, liver/kidney failure or systemic rheumatic diseases (including rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus) Uncontrolled diabetes (defined as HbA1c >7.0% within 3 months prior to enrolment)24 or infectious diseases Uncontrolled diabetes (defined as HbA1c >7.0% within 3 months prior to enrolment)24 or infectious diseases Cognitive impairment or severe mental illness Cognitive impairment or severe mental illness Pregnancy or breastfeeding. Pregnancy or breastfeeding. Withdrawal or termination of individual participants Participants will retain the right to withdraw from the study at any time without penalty, and their decision to do so will not adversely affect the clinical care they will receive through their respective healthcare institutions or established treatment protocols. The principal investigator (PI) will retain the authority to discontinue a participant’s involvement in the study if safety concerns arise, including but not limited to (1) emergence of adverse clinical events compromising subject safety, (2) development of protocol-exclusionary medical conditions or (3) identification of previously undiagnosed disorders, rendering continued participation non-compliant with inclusion/exclusion criteria. Such protocol-defined discontinuation decisions are made according to ethical guidelines and IRB requirements. Randomisation and masking Eligible patients will be randomly assigned (1:1) to the dexamethasone palmitate or dexamethasone group. Stratification and blocking strategies will be used to address potential imbalances during randomisation. The centre will implement stratification to account for potential variations in different clinical institutions. Stratification will also be applied based on the diagnosis of diabetes mellitus and the type of surgery to ensure balanced group allocation. The length of the randomly permuted block will be set to six. Randomisation will be performed using a centralised web-based tool by an independent researcher who will only participate in the randomisation and blinding of this study and will not participate in further steps or analysis of the INDEX study. The researcher will be blinded to the participants’ information. All researchers responsible for the postoperative follow-up and data analysis will be unaware of the grouping. Dexamethasone palmitate is a white suspension, and dexamethasone is a transparent solution; therefore, anaesthesiologists will know the assignment of the type of intervention. The participants and surgeons may also be able to understand the assigned group. The biostatistician involved in this study will not be able to access the data or obtain any results. She/he will remain blinded until the 1 month result evaluation is completed, and the final dataset is locked. Study intervention All the patients will provide written informed consent to participate in the study. In each arm, eligible participants will be randomised into the dexamethasone palmitate and dexamethasone groups after assessment by a blinded investigator. This dose of dexamethasone palmitate can be converted to an equivalent dose of dexamethasone (conversion factor: 4 mg dexamethasone palmitate=2.5 mg dexamethasone). Patients in the dexamethasone palmitate group will receive an intravenous injection of dexamethasone palmitate 8 mg (containing 5 mg dexamethasone) after anaesthesia induction and before surgical incision. The study medication will be prepared in a volume of 2 mL in a 5-mL syringe. Patients in the dexamethasone group will receive intravenous injections of dexamethasone 5 mg after anaesthesia induction and before surgical incision. The research drug will be prepared by an attending anaesthetist who is not a research team member and will not participate in the anaesthesia or follow-up of the study participants. Procedure In the operating room, patients are continuously monitored using electrocardiography, pulse oximetry (SpO2), blood pressure and end-tidal carbon dioxide concentration monitoring. Intravenous injection of 0.05 mg/kg midazolam is administered before anaesthesia induction. The induction phase of general anaesthesia will begin with the administration of intravenous (IV) medications. Propofol (1.5–2.5 mg/kg) will be used to induce unconsciousness rapidly. Sufentanil (0.1–0.3 µg/kg) will be administered to provide analgesia and blunt the stress response. Finally, the neuromuscular blocking agent, cisatracurium (0.15–0.2 mg/kg), will be given to facilitate endotracheal intubation. Once the patient is fully relaxed, the anaesthesiologist will insert a breathing tube and connect it to a ventilator. During the maintenance phase of general anaesthesia, anaesthesia will be maintained using a combination of inhaled and intravenous agents after intubation. Sevoflurane (1%–2.5%) will be delivered via the anaesthesia machine to maintain consciousness, whereas propofol (3–8 mg/kg/h) may be infused to supplement anaesthetic depth. The bispectral (BIS) index will be maintained between 40 and 60. Remifentanil (0.05–0.2 µg/kg/min) will be infused to provide continuous analgesia and titrated according to the discretion of the anaesthetist. Cisatracurium will be titrated to maintain muscle relaxation. The anaesthesiologist will continuously monitor the patient’s vital signs by adjusting the concentrations of sevoflurane, propofol and remifentanil to ensure adequate anaesthesia and haemodynamic stability. The administration of sevoflurane, propofol and remifentanil will gradually reduce as the surgery concludes. The effects of cisatracurium can wear off, and the patient’s breathing is supported until they regain sufficient respiratory function. Once the patient demonstrates the ability to breathe independently with protective reflexes, the endotracheal tube will be removed. Postoperative care protocol A standardised clinical pathway will be established and implemented for each patient undergoing endoscopic surgery. After recovery from anaesthesia in the operating room, all patients will be transferred to the PACU for approximately 2 hours. Then, they will be sent back to the ward. Postoperatively, antiemetic therapy will be administered according to the patient’s needs. The plan for reducing PONV will be the same for all patients. The first-line antiemetic is metoclopramide (10 mg). If PONV persists for >30 min, 5 mg of ondansetron will be administered. Postoperative antiemetic use (frequency, total intake and type) will be recorded. Outcomes The primary endpoint will be the incidence of PONV within the first 24 hours postoperatively. PONV will be defined as any nausea, emetic episodes (vomiting or retching) or both.25 Nausea is defined as an unpleasant sensation with an urge to vomit. Vomiting is defined as the physical event of forcefully expelling gastric contents through the mouth. Retching refers to the forced movement of gastrointestinal contents without the actual expulsion of vomitus. Secondary outcomes will be as follows: Incidence of PONV at 6 hours, 48 hours and 72 hours postoperatively. Incidence of PONV at 6 hours, 48 hours and 72 hours postoperatively. Incidences of postoperative nausea and postoperative vomiting, at 6, 24, 48 and 72 hours postoperatively. Incidences of postoperative nausea and postoperative vomiting, at 6, 24, 48 and 72 hours postoperatively. The number of vomiting or retching episodes (separate episodes defined as those occurring ≥5 min apart) within 6 hours, 24 hours, 48 hours and 72 hours postoperatively. The number of vomiting or retching episodes (separate episodes defined as those occurring ≥5 min apart) within 6 hours, 24 hours, 48 hours and 72 hours postoperatively. Severity of PONV at 6, 24, 48 and 72 hours postoperatively. PONV severity will be measured using a simplified PONV impact scoring system.26 The simplified PONV impact scoring system evaluates nausea impact and vomiting frequency scores. Nausea impact subscale scores will be rated using visual analogue scales (VAS) (0=no impact to 10=maximum impact). VAS scores will be converted to 0–3 points by using predefined thresholds. The vomiting frequency scores are categorised as follows: 0 for no episodes, 1 for 1–2 episodes, 2 for 3–5 episodes and 3 for ≥6 episodes. The total score will be calculated as the sum of the VAS-derived nausea impact score and vomiting frequency score, and 5 points will be defined as clinically significant PONV. Severity of PONV at 6, 24, 48 and 72 hours postoperatively. PONV severity will be measured using a simplified PONV impact scoring system.26 The simplified PONV impact scoring system evaluates nausea impact and vomiting frequency scores. Nausea impact subscale scores will be rated using visual analogue scales (VAS) (0=no impact to 10=maximum impact). VAS scores will be converted to 0–3 points by using predefined thresholds. The vomiting frequency scores are categorised as follows: 0 for no episodes, 1 for 1–2 episodes, 2 for 3–5 episodes and 3 for ≥6 episodes. The total score will be calculated as the sum of the VAS-derived nausea impact score and vomiting frequency score, and 5 points will be defined as clinically significant PONV. Participants’ satisfaction with PONV management at 6, 24, 48 and 72 hours postoperatively. Participant satisfaction will also be rated using a VAS (0=very dissatisfied to 10=most satisfied imaginable). Participants’ satisfaction with PONV management at 6, 24, 48 and 72 hours postoperatively. Participant satisfaction will also be rated using a VAS (0=very dissatisfied to 10=most satisfied imaginable). Use of rescue antiemetic drugs (frequency, total intake amount and type) at 0–24 hours, 24–48 hours and 48–72 hours postoperatively. Use of rescue antiemetic drugs (frequency, total intake amount and type) at 0–24 hours, 24–48 hours and 48–72 hours postoperatively. The quality of postoperative recovery will be assessed using the 15-item quality of recovery scoring system [QoR-15]23 27 at 24 and 48 hours postoperatively, discharge and 1 month postoperatively. The quality of postoperative recovery will be assessed using the 15-item quality of recovery scoring system [QoR-15]23 27 at 24 and 48 hours postoperatively, discharge and 1 month postoperatively. The VAS scores will assess pain intensity at 6, 24, 48 and 72 hours postoperatively. The VAS scores will assess pain intensity at 6, 24, 48 and 72 hours postoperatively. Postoperative length of stay (LOS) will also be recorded. Postoperative length of stay (LOS) will also be recorded. Safety outcomes will include hypotension (defined as a reduction in mean arterial pressure >30% of the baseline for at least 1 min), bradycardia (defined as heart rate <50 beats/min for at least 1 min), hypertension (defined as an increase in mean arterial pressure >30% of the baseline for at least 1 min) and tachycardia (defined as HR >100 beats/min for at least 1 min) during anaesthesia and in the PACU. Haemodynamic event interventions (ephedrine, phenylephrine, atropine, urapidil or esmolol), headache, restlessness, anxiety, dizziness, nightmares or hallucinations occurring after surgery will be recorded in detail. Additionally, blood glucose levels at 48 hours after surgery will also be monitored. Safety outcomes will include hypotension (defined as a reduction in mean arterial pressure >30% of the baseline for at least 1 min), bradycardia (defined as heart rate <50 beats/min for at least 1 min), hypertension (defined as an increase in mean arterial pressure >30% of the baseline for at least 1 min) and tachycardia (defined as HR >100 beats/min for at least 1 min) during anaesthesia and in the PACU. Haemodynamic event interventions (ephedrine, phenylephrine, atropine, urapidil or esmolol), headache, restlessness, anxiety, dizziness, nightmares or hallucinations occurring after surgery will be recorded in detail. Additionally, blood glucose levels at 48 hours after surgery will also be monitored. Sample size PONV occurs in 14.0%–26.3% of minimally invasive endoscopic surgical populations.14 17 The sample size is calculated based on our preliminary data, which suggested an absolute risk reduction of 10% in PONV incidence (10% in the dexamethasone palmitate group vs 20% in the dexamethasone group). To detect this difference with 90% power at a two-sided alpha level of 0.05, a total of 528 participants (264 per group) will be required. Accounting for a 10% potential attrition, 588 participants (294 in each arm) will be included to maintain statistical validity after the anticipated sample loss. This calculation assumes a two-sample proportion test (eg, chi-square test) with equal group allocation and independent observations. Data collection and management Plans for assessment and collection of outcomes Before data collection, the outcome assessor will standardise all the objective outcome measures through protocol-specific training. The team will monitor compliance and will proactively contact the participants (phone/email/mail) to ensure adherence to scheduled assessments. Plans to promote participant retention and complete follow‐up To enhance follow-up assessment completion rates, the following strategies will be implemented: (1) provide multiple response formats (online portal, phone interviews, or mailed questionnaires) tailored to participant preferences; (2) systematically verify and update contact information (phone/email/address) at every interaction point; (3) monitor address changes through real-time cross-checks with healthcare system administrative databases; and (4) offer structured compensation (eg, gift cards scaled to assessment duration) to acknowledge participants’ time investment. Data management The PI will oversee all study aspects and ensure quality. Research coordinators will manage and safeguard trial data. An independent Data Safety and Monitoring Board (DSMB), comprising an anaesthesiologist and two statisticians, will ensure data management reproducibility and analysis integrity. The DSMB will review data collection, participant safety, protocol compliance and trial oversight, while also validating key processes, such as enrolment, consent, randomisation, intervention adherence and follow-up. The PI and study team will conduct monthly reviews of all serious, unexpected and on-site AEs for immediate oversight. Complementing this, the DSMB will convene biannually to perform a higher-level, systematic assessment of unblinded safety data. Through its independent analysis of this cumulative evidence, the DSMB is expressly empowered to formulate recommendations to the Pl regarding the trial’s continuation, modification or, should significant safety concerns be identified, its termination. Blinded data collectors uninvolved in other study aspects will document trial data in case report forms. Two independent data professionals (blinded to the allocation) will perform the dual-entry verification using Excel (Microsoft Corp.) post-trial. Electronic data will be stored on password-protected servers, paper records in locked cabinets and deidentified data will be segregated from the identifiers. Security protocols ensure data integrity throughout storage. The electronic data collection system will also be used throughout the research process to record data input or modification traces. Statistical analysis Statistical methods for primary and secondary outcomes Data will be reported using the CONSORT 2025 Declaration Report: Updated Guidelines for Reporting Parallel-Group Randomised Trials. All statistical tests are two-sided, and P<0.05 will be considered statistically significant. The statistician will not know the interventions allocated for analysis. Statistical analyses will be performed using SPSS (version 27.0; SPSS Inc., Armonk, NY, USA). The completeness and normality of the data distribution will be checked (using the Shapiro–Wilk test). Continuous data will be expressed as median (IQR, IQR) and mean (SD, SD), and categorical data will be described as counts (percentages). All treatment outcomes will be expressed as 95% CIs calculated using the Wilson scoring system. Student’s t test or Mann–Whitney U test will be used to compare continuous data, while the chi-square test or Fisher’s exact test will be used to compare categorical data. Primary analysis will be conducted to evaluate between-group differences in the incidence of PONV in the intention to treat (ITT) population within the first 24 hours postoperatively. The ITT population will include all randomised participants regardless of compliance or withdrawal. The primary outcome will be analysed using the chi-square test or Fisher’s exact test. Secondary analyses will be performed using a linear or generalised linear mixed model. Continuous variables (number of vomiting or retching episodes, severity of PONV, participant satisfaction, QoR-15 scores, pain scores, LOS, etc) will be analysed using a linear mixed model. When the residuals of the model are skewed, we will use a generalised linear mixed model instead. A generalised linear mixed model will be used for categorical variables (incidence of postoperative nausea, postoperative vomiting and PONV). Treatment (dexamethasone palmitate or dexamethasone group), time (time points of the measured variable) and time×treatment interaction will be as fixed factors, with the participant included as a random factor. Adjustments will be performed for baseline variables associated with the secondary outcome (P<0.10) by using multivariate analysis and a stepwise backward elimination strategy. Potential covariates for adjustment include sex, duration of anaesthesia and use of intraoperative analgesics. Interim analysis There is no plan to conduct an interim analysis. Therefore, statistical analysts will not be unblinded before data locking unless requested by an independent DSMB. Methods for additional analyses (eg, subgroup analyses) Subgroup analyses of primary outcome will be conducted. Priori-defined subgroups include younger vs older age (split at the median), sex, type of surgery, surgery time (≥ 3 hours vs <3 hours), receiving intravenous infusion (≥ 25 mL/kg vs <25 mL/kg) and diabetes. Methods in analysis to handle protocol non-adherence and any statistical methods to handle missing data We will conduct a sensitivity analysis to evaluate the impact of the missing values of the outcome parameters on the results. If necessary, we will determine a strategy for handling missing data. If the data are ‘completely random’ missing (MCAR), multiple imputations will be used to fill in the missing data in the ITT analysis, thereby preserving the inherent variability of outcome variables. We will create five imputed datasets using the mice package in R. The imputation models will include all analysis variables (the outcome variables and all baseline covariates). The specific imputation methods will be chosen based on variable types: predictive mean matching for continuous variables, logistic regression for binary variables, polytomous regression (‘polyreg’) for unordered categorical variables and proportional odds models (‘polr’) for ordered categorical variables. Plans to give access to the full protocol, participant‐level data and statistical code The complete protocol is described below. After publishing the planned research paper, we plan to share the deidentified data for future research purposes on reasonable request. Discussion As a multicentre, randomised, positive-controlled trial, the INDEX study is designed to provide high-level evidence regarding the efficacy of dexamethasone palmitate. The trial is strengthened by a large sample size of 588 participants, which ensures adequate statistical power to detect a clinically meaningful difference in the primary outcome. Furthermore, prespecified subgroup analyses will allow for the exploration of treatment effect heterogeneity across key demographic and clinical factors. The robustness of the findings will be reinforced by the use of multiple imputation to handle missing data, thereby preserving the integrity of the intention-to-treat analysis. Despite its strengths, this study has several limitations. First, the open-label design may introduce a risk of performance and detection bias. A double-blind design will not be feasible due to the distinct physical appearance of the two formulations—an opaque, white emulsion vs a clear solution—which makes it impossible to blind the participants and clinical staff administering the treatments. To mitigate this limitation, outcome assessors responsible for collecting and recording PONV data will be blinded to group allocation, and strictly objective criteria for PONV (such as the occurrence of vomiting or use of rescue antiemetics) will be applied to minimise subjective interpretation. In future studies, a double-blind, double-dummy design—in which each participant would receive both an intravenous suspension and a solution, with only one being active—could be considered to further reduce potential bias. Second, the generalisability of the findings is limited to patients undergoing elective minimally invasive endoscopic surgery and may not extend to those having open or major procedures, who have a different PONV risk profile. Third, the safety assessment for hyperglycaemia is restricted, as a single blood glucose check at 48 hours may miss delayed or prolonged glycaemic excursions, a particular concern given the sustained-release nature of dexamethasone palmitate and its implications for diabetic patients. Trial status The approved study protocol (Version 1.0) adheres to SPIRIT 2013 guidelines for clinical trial design. As of manuscript submission, active subject enrollment is proceeding at one of the participating centers. Supplementary material Footnotes Funding: This research was supported by the National Key Research and Development Program of China (Nos. 2022YFC3602200, 2022YFC3602201 2022YFC3602203, and 2022YFC3602205) and National Health Commission Capacity Building and Continuing Education Center Cancer Pain Management (PMT1001-1). The funding source had no role in study design, data collection, data analysis, data interpretation, writing of the report or decision to submit the results for publication. Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (https://doi.org/10.1136/bmjopen-2025-106979). Provenance and peer review: Not commissioned; externally peer reviewed. Patient consent for publication: Not applicable. Patient and public involvement: Patients and/or the public were not involved in the design, conduct, reporting or dissemination plans of this research. References Supplementary Materials